Clinical trial · Observational
Comparative Study Between Immediate Surgery Versus Neoadjuvant Chemotherapy for Management of Resectable Pancreatic Cancer
NCT06978322CI-TRIAL-00117792completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This trial aimed to determine whether neoadjuvant chemoradiotherapy improves overall survival compared with upfront surgery, both followed by adjuvant chemotherapy in patients with resectable and borderline resectable pancreatic cancer.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Management | — | UNRESOLVED | — |
| Neoadjuvant Chemotherapy | — | UNRESOLVED | — |
| Resectable Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_BROADER | 0.78 |
| Surgery | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Immediate surgery | Procedure | — | UNRESOLVED |
| Neoadjuvant chemotherapy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Immediate surgery group
- description
- Patients will undergo upfront surgery, then adjuvant chemotherapy.
- interventionNames
- Procedure: Immediate surgery
- label
- Neoadjuvant chemotherapy group
- description
- Patients will undergo neoadjuvant chemotherapy, then surgery.
- interventionNames
- Procedure: Neoadjuvant chemotherapy
Primary outcomes (1)
- measure
- Overall survival rate
- timeFrame
- 1 year post-procedure
- description
- Overall survival will be measured as the time between date of randomization and date of death from any cause or date of last follow-up if alive.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Computed tomography (CT) with pancreatic protocol + vascular mapping * Histopathologically proven malignant by CT-guided or endoscopic ultrasound (EUS)-guided biopsy Resectable pancreatic cancer means no contact of the tumor with the Superior mesenteric artery, Celiac axis \& Common hepatic artery, and contact of the tumor but ≤90° contact with the superior mesenteric vein \& portal vein. Exclusion Criteria: * Borderline resectable \& locally advanced pancreatic cancer * Tumor at the tail of the pancreas. * Metastatic pancreatic cancer * Unfit patients for surgery.
References
Publications (0)
Data not yet available
No reference posted for this study.